{"id":"NCT00968708","sponsor":"Takeda","briefTitle":"Cardiovascular Outcomes Study of Alogliptin in Patients With Type 2 Diabetes and Acute Coronary Syndrome","officialTitle":"A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Cardiovascular Outcomes Following Treatment With Alogliptin in Addition to Standard of Care in Subjects With Type 2 Diabetes and Acute Coronary Syndrome","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2009-09","primaryCompletion":"2013-04","completion":"2013-06","firstPosted":"2009-08-31","resultsPosted":"2014-04-15","lastUpdate":"2014-05-02"},"enrollment":5380,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Diabetes Mellitus, Type 2","Acute Coronary Syndrome"],"interventions":[{"type":"DRUG","name":"Alogliptin","otherNames":["Nesina®","SYR-322","SYR110322"]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"Placebo","type":"EXPERIMENTAL"},{"label":"Alogliptin","type":"EXPERIMENTAL"}],"summary":"The purpose of this study is to evaluate the cardiovascular outcomes of alogliptin, once daily (QD), compared with placebo, in addition to standard of care, in patients with type 2 diabetes mellitus and acute coronary syndrome.","primaryOutcome":{"measure":"Percentage of Participants With Primary Major Adverse Cardiac Events (MACE)","timeFrame":"From randomization until the adjudication cut-off date of May 31 2013 (maximum time on study was 41 months).","effectByArm":[{"arm":"Placebo","deltaMin":11.8,"sd":null},{"arm":"Alogliptin","deltaMin":11.3,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"0.315"},{"comp":"OG000 vs OG001","p":"0.332"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":3,"exclusionCount":3},"locations":{"siteCount":908,"countries":["United States","Argentina","Australia","Austria","Belgium","Brazil","Bulgaria","Canada","Chile","Colombia","Croatia","Czechia","Denmark","Egypt","Finland","France","Germany","Greece","Guatemala","Hong Kong","Hungary","India","Israel","Italy","Japan","Kuwait","Latvia","Lithuania","Malaysia","Mexico","New Zealand","Peru","Philippines","Poland","Portugal","Puerto Rico","Romania","Russia","Serbia","Slovakia","South Africa","South Korea","Spain","Sweden","Taiwan","Thailand","Turkey (Türkiye)","Ukraine","United Arab Emirates","United Kingdom"]},"refs":{"pmids":["34872085","32493335","31902327","30371278","29848776","29769203","29581078","29064626","28275958","28246236","27289121","25765696","23992602","21982652"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":952,"n":2679},"commonTop":["Hypertension","Renal impairment","Hypoglycaemia","Blood creatine phosphokinase increased","Angina pectoris"]}}